Joshua Seitz focuses his practice on patent prosecution and litigation for life sciences companies. Dr. Seitz has contributed to patent litigation matters and inter partes reviews involving a wide breadth of technologies, including pharmaceuticals, monoclonal antibodies, genome sequencers, and medical devices. In addition, he has prepared and prosecuted patents for numerous clients in the biopharma and high-tech industries. Dr. Seitz also has experience in due diligence and freedom-to-operate analyses, as well as the preparation of non-infringement and invalidity opinions.

Dr. Seitz holds a PhD in Organic Chemistry from SUNY Stony Brook, where he worked in the laboratory of Dr. Iwao Ojima. He has published peer-reviewed scientific papers on topics ranging from synthetic organic methodology to the preclinical development of taxane-based drug conjugates. After graduate school, he held a post-doctoral position at the California Institute for Biomedical Research, where he worked with Dr. Peter Schultz on the synthesis and development of tissue-targeted therapeutics, including novel antibody-drug conjugates. In the course of his research, Dr. Seitz has worked on a variety of scientific programs, including small molecule therapeutics, nanoparticle formulation, ADCs, tissue-targeted drug conjugates, and switchable CAR-Ts.


  • JD, Santa Clara University School of Law, 2018, summa cum laude, Order of the Coif
  • PhD, Organic Chemistry, State University of New York at Stony Brook, 2013
  • BS, Chemistry, University of Vermont, 2007
  • California

Email Disclaimer